Posted on 7/2/2026
In 2026, cold-chain leaders are moving from reactive approaches (download a logger after delivery and hope for the best) to proactive, in-transit control—where packaging, sensors, and decision-making work together while the shipment is still recovera
Temperature excursions aren't a "minor deviation"—they're a high-stakes failure mode that can destroy product efficacy, trigger investigations, and derail patient supply. Industry resources commonly cite up to ~$35B in annual pharma losses tied to cold-chain breakdowns and temperature-controlled logistics failures.
In 2026, cold-chain leaders are moving from reactive ap...